cabergoline has been researched along with Sexual Dysfunction, Physiological in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hartmann, U; Jung, S; Kahl, KG; Keil, L; Krüger, THC; Leeners, B; Wittfoth, M | 1 |
| Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E | 1 |
| Bronstein, MD; Espinosa, E; Glezer, A; Greenman, Y; Mendoza, V; Mercado, M; Popovic, V; Shimon, I; Sosa, E; Tirosh, A | 1 |
| Chapman, IM; De Sousa, SM; Falhammar, H; Torpy, DJ | 1 |
| Anholm, C; Baltzar, MT; Petersen, CD | 1 |
| Freed, DJ; Gillam, MP; Middler, S; Molitch, ME | 1 |
| Biondi, B; Briganti, F; Cappabianca, P; Colao, A; Faggiano, A; Lombardi, G; Pivonello, R; Sarno, AD; Somma, CD | 1 |
2 trial(s) available for cabergoline and Sexual Dysfunction, Physiological
| Article | Year |
|---|---|
Lack of Increase in Sexual Drive and Function After Dopaminergic Stimulation in Women.
Topics: Adult; Arousal; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Humans; Sexual Behavior; Sexual Dysfunction, Physiological | 2018 |
Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Female; Follow-Up Studies; Galactose; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Sex Characteristics; Sexual Dysfunction, Physiological; Treatment Outcome; Visual Fields; Weight Gain | 2003 |
5 other study(ies) available for cabergoline and Sexual Dysfunction, Physiological
| Article | Year |
|---|---|
Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cabergoline; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Haloperidol; Humans; Hyperprolactinemia; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Prolactin; Prospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Sexual Dysfunction, Physiological; Sulpiride | 2013 |
Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Child; Ergolines; Female; Galactorrhea; Headache; Hormone Antagonists; Humans; Male; Middle Aged; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Sexual Dysfunction, Physiological; Treatment Outcome; Tumor Burden; Vision Disorders; Young Adult | 2016 |
Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
Topics: Adult; Aged; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hypogonadism; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Sexual Dysfunction, Physiological | 2017 |
[Hyperprolactin as cause of hypoactive sexual desire in men].
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Libido; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Sexual Dysfunction, Physiological | 2012 |
The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Bromocriptine; Cabergoline; Dopamine Agonists; Enzyme Inhibitors; Ergolines; Hormone Replacement Therapy; Humans; Magnetic Resonance Imaging; Male; Nitriles; Pituitary Neoplasms; Prolactin; Prolactinoma; Sexual Dysfunction, Physiological; Testosterone; Treatment Outcome; Triazoles | 2002 |